Quarterly report pursuant to Section 13 or 15(d)

Warrants

v3.22.4
Warrants
9 Months Ended
Oct. 31, 2022
Warrants  
Warrants

Note 12. Warrants

 

On April 19, 2022, two warrants were exercised for a total of 500,000 shares of common stock resulting in the Company receiving $0.5 million.

 

On April 19, 2022, the holder of the 250,000 shares of Series C Preferred Stock received a warrant to purchase 25,000 shares of common stock at the price of $9.00 per share.

 

On June 3, 2022, the Law Offices of Carl G. Hawkins exercised their warrant acquiring 35,000 shares at the strike price of $1.00 per share through the conversion of the accounts payable owed by the Company for services provided. The shares were issued in the name of Carl G. Hawkins.

 

On June 15, 2022, a former employee’s warrants for 125,000 shares of common stock expired, which was three months after they left the Company.

 

On October 31, 2022, two warrants were exercised for a total of 250,000 shares of common stock, resulting in the Company having a receivable for $0.3 million. Since the receivable is from a stockholder, it is recorded as a contra-equity account.

 

A summary of warrant activity for nine months ended October 31, 2022 is as follows:

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

Conversion

 

 

 

Shares

 

 

Price

 

 

 

 

 

 

 

 

Warrants outstanding at January 31, 2022

 

 

4,991,000

 

 

$

2.83

 

Expired

 

 

(875,000

)

 

 

1.71

 

Exercised

 

 

(785,000

)

 

 

1.00

 

Granted

 

 

25,000

 

 

 

9.00

 

Warrants outstanding at October 31, 2022

 

 

3,356,000

 

 

$

3.60

 

 

During the three months ended October 31, 2022, stock based compensation expense related to warrant grants was $641,000, which consisted of grants to employees of $366,000, directors of $209,000, and consultants of $66,000. During the nine months ended October 31, 2022, stock based compensation expense related to warrant grants was $1,915,000, which consisted of grants to employees of $1,090,000, directors of $628,000, and consultants of $197,000. During the three and nine months ended October 31, 2021, there was no stock based compensation expense associated with warrant grants.